The Filing Desk

Neurogene

NGNE · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

NGNE · Last close · November 13, 2026
$23.93
Value Neurogene yourself

Neurogene's revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$78 million. The diluted share count rose 21.4%.

Neurogene Inc. Latest fiscal year ended December 31, 2025 10-K filed March 24, 2026 · 0001404644-26-000019 Updated
Revenue
$0M
100.0%
Net margin
—
 
Net income
−$90M
 
Free cash flow
−$78M
 
Return on equity
−31.4%
1.1 pts
Market cap
$663M
Nov 13 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Operating margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Net margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Neurogene does

Neurogene is a clinical-stage biotechnology company, meaning its medicines are still being tested in people. It develops genetic medicines for rare neurological diseases that it says conventional gene therapy cannot address well. It was founded in 2018 and has no products approved for sale.

Its lead program, NGN-401, is for Rett syndrome, a severe, progressive disease of brain development. It uses a harmless virus, called an AAV, to carry a gene into the brain, and the company's EXACT technology, which uses microRNA-based circuits to keep the gene's output at a useful level. NGN-401 is given once, through a procedure that delivers it into the fluid-filled spaces of the brain. Neurogene is running a registrational trial, one meant to support an approval request, in females with Rett syndrome aged three and above. It expects to finish dosing in the second quarter of 2026.

It makes the clinical supplies itself at its own manufacturing facility in Houston, Texas. It has paid for its work with outside capital from selling stock and warrants and has not earned product revenue.

Its biggest risks, as it describes them

  • It has a limited operating history, no products for sale and no completed clinical trials.
  • It depends mainly on NGN-401, and its trial may not succeed.
  • It will need substantial more capital, or may have to cut trials and programs.
  • Its gene therapies use one type of AAV delivery vehicle, which carries its own risks.
  • Trial participants may suffer side effects, and competitors are working on the same diseases.
From Neurogene's annual report on Form 10-K, filed March 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Neurogene lost money in fiscal 2025: a net loss of $90 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments14282197312269
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—−28,258.5x−4,631.9x−6,883.8x−20,665.6x
Current ratio16.7x12.7x8.7x20.8x16.6x
Quick ratio16.7x12.7x8.7x20.8x16.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Neurogene's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Neurogene reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''6.1514.5311.14
Accruals ratio9.1%−1.6%−4.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assets———
Current ratio roseFailPassFail
Share count didn't rise——Fail
Gross margin rose———
Revenue rose relative to assets—PassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Neurogene side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
NeurogeneFY25−100.0%—————
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Arbutus BiopharmaFY25128.2%−271.0%−281.4%——3Compare
ADMA BiologicsFY2519.6%37.5%5.5%39.5%−0.1x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——25————010
Revenue growth—————————−100.0%
Gross profit——————————
Research and development2836424243948446175
Operating income−38−51−33−71−34−61−56−56−83−103
Net income−37−50−32−69−33−61−55−36−75−90
Diluted EPS (US$)−1.96−2.14−1.34−2.57−0.64−1.10−1.04—−4.28−4.24
Diluted shares (millions)19242427525555—1821
Cash flow
Cash from operations−30−45−32−15−25−48−53−51−71−77
Capital expenditure1001232011
Free cash flow−31−45−32−16−27−51−55−52−71−78
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation245861211814
Balance sheet at fiscal year end
Cash and short-term investments32527714319314282197312269
Debt incl. finance leases——————————
Total assets15411078147210163109223336289
Total liabilities101155192011362524
Shareholders' equity1459973142191−92−146186310265
Margins and ratios
Gross margin——————————
Operating margin——−130.5%—————−8,930.3%—
Net margin——−126.3%—————−8,123.7%—
Free cash flow margin——−126.5%—————−7,720.1%—
Rule of 40 (growth + FCF margin)——————————
Return on capital——————————
Return on equity−29.2%−41.2%−36.8%−64.8%−20.0%−122.2%—−180.3%−30.3%−31.4%
Return on assets−27.6%−37.9%−33.6%−61.8%−18.6%−32.5%−40.5%−21.9%−26.9%−28.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Neurogene's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Neurogene.